Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 2.32
MDVN's Cash to Debt is ranked lower than
70% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. MDVN: 2.32 )
Ranked among companies with meaningful Cash to Debt only.
MDVN' s 10-Year Cash to Debt Range
Min: 1.1  Med: 9999.00 Max: No Debt
Current: 2.32
Equity to Asset 0.51
MDVN's Equity to Asset is ranked lower than
68% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. MDVN: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
MDVN' s 10-Year Equity to Asset Range
Min: -0.02  Med: 0.40 Max: 0.99
Current: 0.51
-0.02
0.99
Interest Coverage 12.99
MDVN's Interest Coverage is ranked lower than
90% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MDVN: 12.99 )
Ranked among companies with meaningful Interest Coverage only.
MDVN' s 10-Year Interest Coverage Range
Min: 12.99  Med: 10000.00 Max: 9999.99
Current: 12.99
12.99
9999.99
F-Score: 7
Z-Score: 13.29
M-Score: -0.82
WACC vs ROIC
6.79%
240.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 38.66
MDVN's Operating margin (%) is ranked higher than
94% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. MDVN: 38.66 )
Ranked among companies with meaningful Operating margin (%) only.
MDVN' s 10-Year Operating margin (%) Range
Min: -510.27  Med: -62.99 Max: 66.67
Current: 38.66
-510.27
66.67
Net-margin (%) 38.14
MDVN's Net-margin (%) is ranked higher than
94% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. MDVN: 38.14 )
Ranked among companies with meaningful Net-margin (%) only.
MDVN' s 10-Year Net-margin (%) Range
Min: -496.58  Med: -54.45 Max: 38.91
Current: 38.14
-496.58
38.91
ROE (%) 102.88
MDVN's ROE (%) is ranked higher than
99% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. MDVN: 102.88 )
Ranked among companies with meaningful ROE (%) only.
MDVN' s 10-Year ROE (%) Range
Min: -862.65  Med: -53.26 Max: 105.07
Current: 102.88
-862.65
105.07
ROA (%) 43.02
MDVN's ROA (%) is ranked higher than
98% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. MDVN: 43.02 )
Ranked among companies with meaningful ROA (%) only.
MDVN' s 10-Year ROA (%) Range
Min: -80.48  Med: -12.69 Max: 42.39
Current: 43.02
-80.48
42.39
ROC (Joel Greenblatt) (%) 282.87
MDVN's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. MDVN: 282.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDVN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -201825  Med: -4226.22 Max: 299.98
Current: 282.87
-201825
299.98
Revenue Growth (3Y)(%) 113.40
MDVN's Revenue Growth (3Y)(%) is ranked higher than
97% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. MDVN: 113.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDVN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -100.00 Max: 113.4
Current: 113.4
0
113.4
» MDVN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

MDVN Guru Trades in Q3 2014

John Burbank 2,451 sh (New)
Jim Simons 108,728 sh (New)
Paul Tudor Jones 11,585 sh (New)
Joel Greenblatt 13,970 sh (New)
Mario Gabelli Sold Out
» More
Q4 2014

MDVN Guru Trades in Q4 2014

Ken Fisher 2,532 sh (New)
Steven Cohen 24,200 sh (New)
Jim Simons 257,100 sh (+136.46%)
Joel Greenblatt 31,518 sh (+125.61%)
John Burbank Sold Out
Paul Tudor Jones 5,919 sh (-48.91%)
» More
Q1 2015

MDVN Guru Trades in Q1 2015

Louis Moore Bacon 15,000 sh (New)
Joel Greenblatt 150,526 sh (+377.59%)
Jim Simons 434,231 sh (+68.90%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Ken Fisher 2,400 sh (-5.21%)
» More
Q2 2015

MDVN Guru Trades in Q2 2015

Ken Fisher 2,400 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MDVN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 32.62
MDVN's P/E(ttm) is ranked higher than
61% of the 221 Companies
in the Global Biotechnology industry.

( Industry Median: 43.00 vs. MDVN: 32.62 )
Ranked among companies with meaningful P/E(ttm) only.
MDVN' s 10-Year P/E(ttm) Range
Min: 32.13  Med: 40.95 Max: 329.46
Current: 32.62
32.13
329.46
Forward P/E 22.73
MDVN's Forward P/E is ranked higher than
55% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. MDVN: 22.73 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 32.20
MDVN's PE(NRI) is ranked higher than
62% of the 219 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. MDVN: 32.20 )
Ranked among companies with meaningful PE(NRI) only.
MDVN' s 10-Year PE(NRI) Range
Min: 32.12  Med: 40.94 Max: 325.93
Current: 32.2
32.12
325.93
P/B 17.42
MDVN's P/B is ranked lower than
90% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. MDVN: 17.42 )
Ranked among companies with meaningful P/B only.
MDVN' s 10-Year P/B Range
Min: 0.7  Med: 36.38 Max: 1848.25
Current: 17.42
0.7
1848.25
P/S 11.91
MDVN's P/S is ranked lower than
51% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. MDVN: 11.91 )
Ranked among companies with meaningful P/S only.
MDVN' s 10-Year P/S Range
Min: 4.54  Med: 24.41 Max: 563.33
Current: 11.91
4.54
563.33
PFCF 33.01
MDVN's PFCF is ranked higher than
61% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 45.41 vs. MDVN: 33.01 )
Ranked among companies with meaningful PFCF only.
MDVN' s 10-Year PFCF Range
Min: 3.04  Med: 39.41 Max: 253.5
Current: 33.01
3.04
253.5
POCF 32.01
MDVN's POCF is ranked higher than
54% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 35.29 vs. MDVN: 32.01 )
Ranked among companies with meaningful POCF only.
MDVN' s 10-Year POCF Range
Min: 3.03  Med: 38.20 Max: 202.8
Current: 32.01
3.03
202.8
EV-to-EBIT 27.09
MDVN's EV-to-EBIT is ranked higher than
64% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. MDVN: 27.09 )
Ranked among companies with meaningful EV-to-EBIT only.
MDVN' s 10-Year EV-to-EBIT Range
Min: -658.8  Med: -26.75 Max: 156.7
Current: 27.09
-658.8
156.7
Current Ratio 7.02
MDVN's Current Ratio is ranked higher than
63% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. MDVN: 7.02 )
Ranked among companies with meaningful Current Ratio only.
MDVN' s 10-Year Current Ratio Range
Min: 1.46  Med: 3.89 Max: 27.3
Current: 7.02
1.46
27.3
Quick Ratio 7.02
MDVN's Quick Ratio is ranked higher than
64% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. MDVN: 7.02 )
Ranked among companies with meaningful Quick Ratio only.
MDVN' s 10-Year Quick Ratio Range
Min: 1.46  Med: 3.89 Max: 27.3
Current: 7.02
1.46
27.3
Days Sales Outstanding 61.41
MDVN's Days Sales Outstanding is ranked lower than
51% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. MDVN: 61.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDVN' s 10-Year Days Sales Outstanding Range
Min: 34.21  Med: 94.91 Max: 143.37
Current: 61.41
34.21
143.37

Valuation & Return

vs
industry
vs
history
Price/Net Cash 71.77
MDVN's Price/Net Cash is ranked lower than
93% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. MDVN: 71.77 )
Ranked among companies with meaningful Price/Net Cash only.
MDVN' s 10-Year Price/Net Cash Range
Min: 3  Med: 18.07 Max: 191.56
Current: 71.77
3
191.56
Price/Net Current Asset Value 29.94
MDVN's Price/Net Current Asset Value is ranked lower than
88% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. MDVN: 29.94 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MDVN' s 10-Year Price/Net Current Asset Value Range
Min: 2.88  Med: 34.83 Max: 364.25
Current: 29.94
2.88
364.25
Price/Tangible Book 22.88
MDVN's Price/Tangible Book is ranked lower than
90% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. MDVN: 22.88 )
Ranked among companies with meaningful Price/Tangible Book only.
MDVN' s 10-Year Price/Tangible Book Range
Min: 0.3  Med: 14.23 Max: 1152.75
Current: 22.88
0.3
1152.75
Price/Projected FCF 26.80
MDVN's Price/Projected FCF is ranked lower than
81% of the 136 Companies
in the Global Biotechnology industry.

( Industry Median: 5.34 vs. MDVN: 26.80 )
Ranked among companies with meaningful Price/Projected FCF only.
MDVN' s 10-Year Price/Projected FCF Range
Min: 1.92  Med: 9.38 Max: 240
Current: 26.8
1.92
240
Price/Median PS Value 0.49
MDVN's Price/Median PS Value is ranked higher than
86% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. MDVN: 0.49 )
Ranked among companies with meaningful Price/Median PS Value only.
MDVN' s 10-Year Price/Median PS Value Range
Min: 0.18  Med: 0.69 Max: 2.87
Current: 0.49
0.18
2.87
Price/Graham Number 5.40
MDVN's Price/Graham Number is ranked lower than
66% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. MDVN: 5.40 )
Ranked among companies with meaningful Price/Graham Number only.
MDVN' s 10-Year Price/Graham Number Range
Min: 5.36  Med: 8.11 Max: 21.35
Current: 5.4
5.36
21.35
Earnings Yield (Greenblatt) (%) 3.65
MDVN's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. MDVN: 3.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDVN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.6  Med: 2.70 Max: 3.8
Current: 3.65
0.6
3.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:WMD.Germany,
Medivation Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI enzalutamide capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics Inc or MPT, Medivation Neurology Inc or MNI, Medivation Technologies Inc, or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
» More Articles for MDVN

Headlines

Articles On GuruFocus.com
Medivation Announces Second Quarter 2015 Financial Results Teleconference on August 6, 2015 Jul 16 2015 
Medivation Voted Three Years in a Row Among Top Workplaces in the San Francisco Bay Area Jun 29 2015 
current Apr 10 2015 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
Wedbush Weighs in on Medivation Following Phase II TERRAIN Study Results Feb 03 2015 
Weekly CEO Sells Highlight: QAD Inc, Orbitz Worldwide Inc, Constellation Brands Inc, and Medivation Jan 25 2015 
Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase in PFS as Compare Jan 22 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Medivation and Astellas Announce Phase 3 Study of Enzalutamide in Men With High-Risk, Hormone-Sensit Oct 30 2014 
A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio Aug 15 2014 

More From Other Websites
MEDIVATION, INC. Files SEC form 8-K, Other Events Jul 31 2015
Trending Now: MDVN Jul 29 2015
Medivation Announces Second Quarter 2015 Financial Results Teleconference on August 6, 2015 Jul 16 2015
Medivation Announces Second Quarter 2015 Financial Results Teleconference on August 6, 2015 Jul 16 2015
Vital Therapies Announces Appointment of Former Medivation Chief Commercial Officer Cheryl Cohen to... Jul 15 2015
Medivation (MDVN) Stock Falling After Earnings Estimates Cut Jul 13 2015
Biotech Investors That Own This Name Could See 50 Percent Near Term Upside, After Selloff Jul 10 2015
Medivation Voted Three Years in a Row Among Top Workplaces in the San Francisco Bay Area Jun 29 2015
Medivation Voted Three Years in a Row Among Top Workplaces in the San Francisco Bay Area Jun 29 2015
MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 19 2015
Medivation to Redeem Outstanding Convertible Notes Due 2017 Jun 19 2015
Medivation to Redeem Outstanding Convertible Notes Due 2017 Jun 19 2015
Medivation and Astellas Announce Enrollment of the First Patients in Advanced Prostate Cancer... Jun 17 2015
Medivation and Astellas Announce Enrollment of the First Patients in Advanced Prostate Cancer... Jun 17 2015
New Enzalutamide Data in Triple-Negative Breast Cancer Presented at the 2015 American Society of... Jun 01 2015
New Enzalutamide Data in Triple-Negative Breast Cancer Presented at the 2015 American Society of... Jun 01 2015
New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of... Jun 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK